According to The Fly, Stock research analysts from BTIG Research assumed coverage on Vaxcyte’s (NASDAQ: PCVX) shares in a research report that was delivered on Thursday to clients and investors. The investment firm recommended “buying” the stock and established a price target of $69.00. A possible gain of 59.17% from the stock’s previous closing price is implied by the price objective that BTIG Research established.

The stock has received commentary from several other analysts as well. In a research note published on November 8, Cantor Fitzgerald increased their price objective on shares of Vaxcyte from $55.00 to $70.00. The price objective that Bank of America has set for Vaxcyte shares has been increased to $67.00, as stated in a research note published on Monday, October 24.
PCVX shares began trading on Thursday for $43.35 per share. The all-time low for Vaxcyte during the last year was $16.78, while the all-time high was $46.57. The firm’s market capitalization is $3.42 billion, the price-to-earnings ratio is -14.69, and the beta value is 1.12. The moving average for the company over the past 50 days is $31.36, and the moving average over the past 200 days is $26.43.
On Monday, August 22, Senior Vice President Paul Sauer sold 3,000 shares of the company’s stock, as was reported in other news. At an average price of $25.93 per share, the shares were sold for a total of $77,790.00, which brings the total to $77,790.00. At this time, the senior vice president personally possesses 14,687 shares of company stock, which have a value of $380,833.91. The transaction was disclosed in a legal filing submitted to the Securities and Exchange Commission (SEC), and that filing can be located on the website of the SEC. On Monday, September 19, Chief Operating Officer Jim Wassil sold 2,800 shares of the company’s stock. At an average price of $26.11, the shares brought in a total of $73,108.00 when sold. As a result of the transaction, the chief operating officer now owns 42,344 company shares, which have a combined value of $1,105,601.84. The transaction was made public through a filing with the Securities and Exchange Commission, which may be viewed by clicking on the following link: On Monday, August 22, Senior Vice President Paul Sauer sold 3,000 of the company’s shares of stock. A total of 77,790.00 dollars was obtained through the sale of the stock at an average price of $25.93 per share. As a direct result of the transaction, the senior vice president now owns 14,687 shares of the firm, which have a value of $380,833.91. The disclosure for this sale can be found at this location. Insiders sold 87,998 shares of company stock with a total value of $2,649,648 over the most recent three months. 13.70% of the company’s shares are held privately by company insiders.

There has been a recent movement in the proportion of hedge funds in which the corporation invests. Great West Life Assurance Company bought a new investment in Vaxcyte during the third quarter. The value of this new position was roughly $43,000. Amundi paid roughly $64,000 during the year’s second quarter for someone to take a new post at Vaxcyte. At the end of the third quarter, Allspring Global Investments Holdings LLC had a holding in Vaxcyte that was 275.5 percent larger than before. Following the acquisition of an additional 3,198 shares during the most recent fiscal quarter, Allspring Global Investments Holdings LLC now holds a total of 4,359 shares of the company’s stock, which has a value of $104,000. During the second quarter, Virtus ETF Advisers LLC invested roughly 128,000 dollars in purchasing a new investment in Vaxcyte. Last but not least, during the first three months of the year, Amalgamated Bank shelled out nearly $129,000 to fill a new post at Vaxcyte. Institutional investors and hedge funds control a combined total of 86.74% of the company’s outstanding stock.

Vaxcyte, Inc. is a biotechnology vaccine firm in the clinical stage of development. They develop novel protein vaccines to cure or prevent bacterial infectious diseases. The most promising vaccine candidate is VAX-24, an experimental pneumococcal conjugate vaccine with 24 antigens currently undergoing Phase 1/2 clinical testing to treat invasive pneumococcal illness and pneumonia.

The post Membership Collective Group (NYSE:MCG) has been downgraded to Neutral by JPMorgan Chase & Co. appeared first on Best Stocks.